[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Pengyuan Liu\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100535278",false,"NCT06249750","Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer","Inclusion Criteria:\n\n* Histopathologically confirmed diagnosis of PC and clinically confirmed diagnosis of CRPC;\n* Complete and reliable medical history and medical records;\n* No other primary tumors except CRPC;\n* Blood tests, liver function, renal function and electrocardiogram are basically normal;\n* Patients with ECOG score 0\\~3, aged ≥18 years and \\\u003C90 years old;\n* Patients with good compliance, able to accept regular follow-up.\n\nExclusion Criteria:\n\n* History of malignant tumor other than PC within the past 5 years;\n* Severe abnormalities in the patient's laboratory indices may jeopardize patient safety or compromise this study;\n* Accompanied by severe underlying diseases that cannot tolerate this therapy;\n* With acute diseases, such as acute infection, active bleeding;\n* Those who have recently participated in other clinical trials and have not passed the washout period;\n* Those who cannot tolerate systemic heat stress, such as claustrophobic patients;\n* Those who have a history of allergy to the drugs used in the trial;\n* Patients with other reasons for not being able to be enrolled in the study, according to the study doctor.","MALE","18 Years","90 Years",{"count":18,"type":19},60,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","In this study, we propose to use the combination of ET-SPACE NIR irradiation whole-body thermal stimulation, ICI (Tislelizumab), and RTK inhibitor (Anlotinib) in the multimodal treatment of CRPC.",[25],"Metastatic Castration-resistant Prostate Cancer (CRPC)",[27],"hyperthermia, immune checkpoint inhibitor, RTK inhibitor, CRPC","RECRUITING","2024-01-31",{"date":31,"type":32},"2024-02-08","ACTUAL",{"date":34,"type":32},"2024-01-01",{"date":36,"type":19},"2026-12-31",{"name":38,"class":39},"Pengyuan Liu","OTHER",""]